Skip to main content Skip to main navigation menu Skip to site footer

Scoping Review: Effectiveness of NDO-LID as new biomarker for leprosy diagnosis


Leprosy is a chronic infectious disease that continues to be prevalent in over 120 countries worldwide, with over 200,000 cases of leprosy. The challenge in controlling leprosy cases is early diagnosis and identification of new cases. It is very important to diagnose quickly and precisely to prevent further disability due to nerve damage. This scoping review aims to assess the effectiveness of NDO-LID as a diagnostic test. The search strategy covered three main databases: PubMed, Science Direct, and Google Scholar, focusing on peer-reviewed studies published from 2019 to 2023. PRISMA guidelines were followed during the literature search. The keywords "NDO-LID" and "NDO-LID Leprosy" were used in the search to find relevant studies. The review included three articles out of 370 relevant ones. The review encompassed 1953 participants across three studies. Part of the review reported on 11 diagnostic test assessments. NDO-LID can detect leprosy patients in both MB and PB cases. Although NDO-LID has higher sensitivity and specificity values than its comparators, further studies are needed to test the accuracy of the diagnostic test more comprehensively to provide stronger and more convincing evidence.


  1. Salgado CG, Brito AC, Salgado UI, Spencer JS. Leprosy. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al, editors. Fitzpatrick’s Dermatology Ninth Edition Volume 1. New York: McGraw-Hill Education; 2019. p. 2892-919.
  2. Jain S. Dermatology Second Edition. Switzerland: Springer International Publishing AG; 2017. p.220.
  3. PERDOSKI. Panduan Praktik Klinis Bagi Dokter Spesialis Dermatologi Dan Venereologi Indonesia. Jakarta: PERDOSKI; 2021.
  4. Rumondor BB, Prakoeswa AC, Trianita MN, Iswahyudi I, Herwanto N, Listiawan MY, et al. Immunoglobulin AMG Anti Natural Disaccharide Octyl - Leprosy IDRI Diagnostic (NDO-LID) Serologic Test for Leprosy Diagnosis: a Pilot Study. Dermatol Reports [Internet]. 2019 Mar. 29;11(s1). Available from:
  5. Hooij, A. van. Development of immunodiagnostic tests for leprosy: from biomarker discovery to application in endemic areas. Netherlands: Universiteit Leiden; 2021. Retrieved from
  6. Alinda MD, Geani S, Agusni RI, Kusumaputra BH, Reza NR, Prakoeswa CRS, et al. Diagnosis and Management of Leprosy. BIKK [Internet]. 2020 Jul. 31;32(2):149-57. Available from:
  7. WHO. Leprosy [Internet]. 2023. Available from:
  8. Sarode G, Sarode S, Anand R, Patil S, Jafer M, Baeshen H, et al. Epidemiological aspects of leprosy. Dis Mon. 2020 Jul;66(7):100899.
  9. Swe MMM, Phyo AP, Cooper BS, White NJ, Smithuis F, Ashley EA. A systematic review of neglected tropical diseases (NTDs) in Myanmar. PLoS Negl Trop Dis. 2023 Nov 1;17(11):e0011706.
  10. Gautam S, Sharma D, Goel A, Patil SA, Bisht D. Insights into Mycobacterium leprae Proteomics and Biomarkers—An Overview. Proteomes. 2021; 9, 7.
  11. Junior LARF, Sotto MN, Trindade MAB. Leprosy: clinical and immunopathological characteristics. An Bras Dermatol. 2022; 97(3): 338-47.
  12. Gracino ME, Santos BM, Garbelin MV, Nishi V, Silva D, Kondo RN, et al. Leprosy: A systematic review. Int J Dermatol Sci. 2020; 2(1): 8-21.
  13. Romero CP, Castro R, do Brasil PEA, Pereira DR, Pinheiro RO, Toscano CM, et al. Accuracy of rapid point-of-care serological tests for leprosy diagnosis: a systematic review and meta-analysis. Mem Inst Oswaldo Cruz. 2022;117:e220317.
  14. Malhotra KP, Husain N. Laboratory perspectives for Leprosy: Diagnostic, prognostic and predictive tools. Indian J Pathol Microbiol. 2022;65, Suppl S1:300-9.
  15. Silva KKdPe, Oliveira EE, Elias CMM, Pereira IE, Pinheiro RO, Sarno EN, et al. Serum IgA Antibodies Specific to M. leprae Antigens as Biomarkers for Leprosy Detection and Household Contact Tracking. Front Med. 2021; 8:698495.
  16. Lockwood DNJ. In Griffiths CEM, Barker J, Bleiker T, Chaimer R, Creeamer D, editors, Rook’s Textbook of Dermatology, 9th ed, Chichester: John Wiley & Sons, Ltd; 2016, p. 28.1-18.
  17. Sengupta U. Recent Laboratory Advances in Diagnostics and Monitoring Response to Treatment in Leprosy. Indian Dermatol Online J. 2019;10(2):106-14.
  18. Gama RS, Leite LA, Colombo LT, Fraga LAO. Prospects for new leprosy diagnostic tools, a narrative review considering ELISA and PCR assays. Rev Soc Bras Med Trop. 2020 Nov 25;53:e20200197.
  19. Serrano-Coll H, Osorio-Leal Y, Escobar-Builes MV, Cardona-Castro N. Detection of Mycobacterium leprae infection in family clusters from six leprosy-endemic regions in Colombia. Trans R Soc Trop Med Hyg. 2022 May; 116(5): 501–8.
  20. Trianita MN, Rumondor BB, Prakoeswa AC, Iswahyudi I, Adriaty D, Kusumaputra BH,et al. A simpler diagnostic method using blood collection on filter paper to determine anti-natural octyl disaccharide-leprosy infectious disease research institute diagnostic in household contacts of leprosy patients. Dermatol Reports [Internet]. 2019 Mar. 29 11(s1). Available from:
  21. de Oliveira ALG, Fraga VG, Sernizon-Guimarães N, Cardoso MS, Viana AG, Bueno LL, et al. Diagnostic accuracy of tests using recombinant protein antigens of Mycobacterium leprae for leprosy: A systematic review. J Infect Public Health. 2020;13(8):1078-88.
  22. Serrano-Coll H, Muñoz M, Beltrán JC, Cardona-Castro N. High seropositivity against NDO-LID in a group of household contacts of leprosy patients. Are we close to leprosy elimination in Colombia? Pathog Glob Health. 2023 Dec;117(8):727-34.
  23. Gama RS, de Souza MLM, Sarno EN, de Moraes MO, Gonçalves A, Stefani MMA, et al. A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts. PLoS Negl Trop Dis. 2019; 13:1–22.
  24. Leturiondo AL, Noronha AB, do Nascimento MOO, Ferreira CdO, Rodrigues FdC, Moraes MO, et al. Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil. BMC Infect Dis. 2019;19(1):22.
  25. Jian L, Xiujian S, Yuangang Y, Yan X, Lianchao Y, Duthie MS, et al. Evaluation of antibody detection against the NDO-BSA, LID-1 and NDO-LID antigens as confirmatory tests to support the diagnosis of leprosy in Yunnan province, southwest China. Trans R Soc Trop Med Hyg. 2020;114(3):193-9.
  26. Ignotti E, Steinmann P. Perspectives for leprosy control and elimination. Cad Saude Publica. 2020; 36(7): 0-3.
  27. Santos VS, de Souza CDF, Martins-Filho PRS, Cuevas LE. Leprosy: why does it persist among us? Expert Rev Anti Infect Ther. 2020; 18:613–5.
  28. Barbosa AM, Silva SUD, Toledo ACCG, Abreu MAMM. Seroepidemiologic survey of the household contacts of leprosy patients. Rev Assoc Med Bras. 2022; 21;68(10):1389-93.
  29. Wang N, Chu T, Li F, Wang Z, Liu D, Chen M, et al. The role of an active surveillance strategy of targeting household and neighborhood contacts related to leprosy cases released from treatment in a low-endemic area of china. PLoS Negl Trop Dis. 2020; 14:1–11.
  30. Gobbo AR, Bouth RC, Moraes TMP, Pinto P, da Costa PF, Barreto JG, et al. NDO-BSA, LID-1, and NDO-LID Antibody Responses for Infection and RLEP by Quantitative PCR as a Confirmatory Test for Early Leprosy Diagnosis. Front Trop Dis. 2022; 3:850886.

How to Cite

Julianto, R., & Putri, R. D. . (2024). Scoping Review: Effectiveness of NDO-LID as new biomarker for leprosy diagnosis. Intisari Sains Medis, 15(1), 331–335.




Search Panel

Ricky Julianto
Google Scholar
ISM Journal

Rachmah Diana Putri
Google Scholar
ISM Journal